A Phase II/III, Multi-center, Randomized, Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs. ON 01910.Na Combined with Gemcitabine in Patients with Previously Untreated Metastatic Pancreatic Cancer
Phase of Trial: Phase II/III
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Rigosertib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms ONTRAC
- Sponsors Onconova Therapeutics
- 03 Mar 2016 Results published in the Annals of Oncology
- 13 Jul 2015 Status changed from completed to discontinued.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO 2015).